Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines

9 Sept 2015

Abstract excerpt

BACKGROUND: Platinum compounds are the mainstay of chemotherapy for lung cancer. Unfortunately treatment failure remains a critical issue since about 60% of all non-small cell lung cancer (NSCLC) patients display intrinsic platinum resistance. METHODS: We analyzed global gene expression profiles of NSCLC clones surviving a pulse treatment with cisplatin and mapped deregulated signaling networks in silico by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Treatments and Mutations
Share to Microtubule and mitosis dynamics
Share to Wnt/β-catenin signaling in development and cancer

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26353782
DOI: 10.1186/s12885-015-1635-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell linesPMID 26353782Read ↗

A novel role for the tumor suppressor gene <i>ITF2</i> in lung tumorigenesis and chemotherapy responseSemantic proximity Read ↗

A Novel Role for the Tumor Suppressor Gene ITF2 in Lung Tumorigenesis and Chemotherapy ResponseSemantic proximity Read ↗

FOXA1 Targets NEK2 to Mediate Cisplatin Resistance in Lung Adenocarcinoma Cells by Activating DNA Damage RepairSemantic proximity Read ↗

KDM6B Inhibition Enhances Chemotherapeutic Response in Small Cell Lung Cancer via Epigenetic Regulation of Apoptosis and FerroptosisSemantic proximity Read ↗

Transcriptome analysis reveals PRKCA as a potential therapeutic target for overcoming cisplatin resistance in lung cancer through ferroptosisSemantic proximity Read ↗

The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung CancerSemantic proximity Read ↗

Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.Semantic proximity Read ↗

Transcriptome Sequencing Reveals Key Pathways and Genes Associated with Cisplatin Resistance in Lung Adenocarcinoma A549 CellsSemantic proximity Read ↗

Regulation of cisplatin resistance in lung cancer by epigenetic mechanismsSemantic proximity Read ↗

Cisplatin resistance in human lung cancer cells is linked with dysregulation of cell cycle associated proteinsSemantic proximity Read ↗

Super-enhancer-driven HAVCR1 defines cisplatin resistance yet immunotherapy responsiveness in non-small-cell lung cancerSemantic proximity Read ↗

Loss of Cytoplasmic CDK1 Predicts Poor Survival in Human Lung Cancer and Confers Chemotherapeutic ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.